Osteogenic effects of simvastatin-loaded mesoporous titania thin films

LOPEZ-ALVAREZ, MIRIAM; LÓPEZ-PUENTE, VANESA; RODRIGUEZ-VALENCIA, COSME; ANGELOMÉ, PAULA C.; LIZ-MARZAN, LUIS M; SERRA, JULIA; PASTORIZA-SANTOS, ISABEL; GONZALEZ, PIO

BIOMEDICAL MATERIALS

IOP PUBLISHING LTD

Año: 2017

1748-6041

The use of statins in the field of bone regeneration is under current investigation due to the existing demand for non-toxic anabolic agents capable of enhancing bone formation in cases of substantial loss. Simvastatin, a coenzyme currently prescribed in clinics to inhibit cholesterol biosynthesis, has been proven to promote osteogenic differentiation by stimulating bone formation and inhibiting osteoclasts activity. We present the loading of simvastatin in mesoporous TiO2 thin films toward combining the pro-osteogenicproperties of this molecule with the demonstrated bioactivity of titania. TiO2 thin films processing and characterization were carried out, as well as evaluation of MC3T3-E1 preosteoblasts viability when directly incubated with different concentrations of simvastatin, followed by the analysis of osteogenic activity promoted by simvastatin upon loading in the thin films. The accessible porosity of 36 % quantified on the 95±5 nm thick mesoporous thin films, together with pore diameters of 5.5 nm, necks between pores of 2.8 nm and interpore distances of 12±2 nm allow the loading of the simvastatin molecule, as confirmed by FTIR spectroscopy. Simvastatin was found to promote MC3T3-E1 preosteoblastsviability at concentrations ≤ 0.01 g/L, with a cytotoxicity threshold of 0.05g/L. We additionally found that film loadings with 0.001 g/L simvastatin promotes statistically higher MC3T3-E1 pre-osteoblast proliferation whereas a higher concentration of 0.01 g/L leads to statistically higher osteogenic activity (ALP synthesis), after 21 days of incubation, as compared to unloaded films. These results demonstrate the potential of simvastatin local administration based on bioactive mesoporous thin films to promote pro-osteogenic properties. By focusing this strategy on the coating of metallic prostheses, the supply of simvastatin to the target tissue can be favored and risks of systemic side effects will be reduced while enhancing the osteointegration of the implants.